Haleon PLC Sponsored ADR $HLN Shares Sold by Cidel Asset Management Inc.

Cidel Asset Management Inc. lessened its stake in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 19.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 364,453 shares of the company’s stock after selling 86,236 shares during the quarter. Cidel Asset Management Inc.’s holdings in Haleon were worth $3,685,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. SOA Wealth Advisors LLC. increased its stake in Haleon by 60.5% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 3,105 shares of the company’s stock valued at $28,000 after buying an additional 1,170 shares during the period. Citizens National Bank Trust Department lifted its stake in shares of Haleon by 167.4% in the 3rd quarter. Citizens National Bank Trust Department now owns 3,276 shares of the company’s stock worth $29,000 after acquiring an additional 2,051 shares during the period. Atlantic Union Bankshares Corp boosted its holdings in shares of Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after acquiring an additional 2,758 shares in the last quarter. Stance Capital LLC acquired a new position in shares of Haleon during the third quarter worth about $34,000. Finally, Geneos Wealth Management Inc. increased its stake in shares of Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently commented on HLN. Morgan Stanley restated an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Argus raised Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft cut Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a report on Tuesday, January 20th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.33.

Haleon Stock Up 0.2%

Shares of NYSE HLN opened at $9.95 on Monday. The stock has a market capitalization of $44.28 billion, a price-to-earnings ratio of 25.50 and a beta of 0.26. Haleon PLC Sponsored ADR has a 52 week low of $8.71 and a 52 week high of $11.42. The firm has a 50-day moving average price of $10.50 and a 200 day moving average price of $9.89. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47.

Haleon Announces Dividend

The company also recently declared a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be paid a dividend of $0.1307 per share. The ex-dividend date of this dividend is Friday, April 10th. This represents a dividend yield of 251.0%. Haleon’s payout ratio is 28.21%.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.